Author:
Li Ruowen,Qu Wenjie,Liu Qingqing,Tan Yilin,Zhang Wenjing,Hao Yiping,Jiang Nan,Mao Zhonghao,Ye Jinwen,Jiao Jun,Gao Qun,Cui Baoxia,Dong Taotao
Abstract
Abstract
Background
The aim was to develop a personalized survival prediction deep learning model for cervical adenocarcinoma patients and process personalized survival prediction.
Methods
A total of 2501 cervical adenocarcinoma patients from the surveillance, epidemiology and end results database and 220 patients from Qilu hospital were enrolled in this study. We created our deep learning (DL) model to manipulate the data and evaluated its performance against four other competitive models. We tried to demonstrate a new grouping system oriented by survival outcomes and process personalized survival prediction by using our DL model.
Results
The DL model reached 0.878 c-index and 0.09 Brier score in the test set, which was better than the other four models. In the external test set, our model achieved a 0.80 c-index and 0.13 Brier score. Thus, we developed prognosis-oriented risk grouping for patients according to risk scores computed by our DL model. Notable differences among groupings were observed. In addition, a personalized survival prediction system based on our risk-scoring grouping was developed.
Conclusions
We developed a deep neural network model for cervical adenocarcinoma patients. The performance of this model proved to be superior to other models. The results of external validation supported the possibility that the model can be used in clinical work. Finally, our survival grouping and personalized prediction system provided more accurate prognostic information for patients than traditional FIGO stages.
Funder
Clinical Research Center of Shandong University
Scientific Research Foundation of Qilu Hospital of Shandong Universit
Natural Science Foundation of Shandong Province, China
Publisher
Springer Science and Business Media LLC
Subject
Applied Mathematics,Computer Science Applications,Molecular Biology,Biochemistry,Structural Biology
Reference28 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Williams NL, Werner TL, Jarboe EA, Gaffney DK. Adenocarcinoma of the cervix: should we treat it differently? Curr Oncol Rep. 2015;17(4):17.
3. Gadducci A, Guerrieri ME, Cosio S. Adenocarcinoma of the uterine cervix: pathologic features, treatment options, clinical outcome and prognostic variables. Crit Rev Oncol Hematol. 2019;135:103–14.
4. Eifel PJ, et al. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer. 1990;65(11):2507–14.
5. Nosaka K, Horie Y, Shiomi T, Itamochi H, Oishi T, Shimada M, Sato S, Sakabe T, Harada T, Umekita Y. Cytoplasmic maspin expression correlates with poor prognosis of patients with adenocarcinoma of the uterine cervix. Yonago Acta Med. 2015;58(4):151–6.